{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:09:26Z","timestamp":1785283766414,"version":"3.55.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Paul O\u2019Byrne Resident Research Grant from McMaster University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Single oral dose anti-arrhythmic drugs (AADs) are used to cardiovert recent-onset atrial fibrillation (AF); however, the optimal agent is uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a systematic review and network meta-analysis of randomized trials testing single oral dose AADs vs. any comparator to cardiovert AF &amp;lt;7\u2009days duration. We searched MEDLINE, Embase, and CENTRAL to April 2020. The primary outcome was successful cardioversion at timepoint nearest 8\u2009h after administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 12\u2009712 citations, 22 trials (2320 patients) were included. Thirteen trials included patients with some degree of heart failure; 19 included patients with some degree of ischaemic heart disease vs. placebo or rate-control (32% success) at 8\u2009h, flecainide [73%, network odds ratio (OR) 7.6, 95% credible interval (CrI) 4.4\u201314.0], propafenone (70%, OR 4.6, CrI 2.9\u20137.3), and pilsicainide (59%, OR 10.0, CrI 1.8\u201369.0), but not amiodarone (28%, OR 1.0, CrI 0.4\u20132.8) were superior. Flecainide (OR 7.5, CrI 2.6\u201324.0) and propafenone (OR 4.5, CrI 1.6\u201313.0) were superior to amiodarone; propafenone vs. flecainide did not statistically differ (OR 0.6, CrI 0.3\u20131.1). At longest follow-up, amiodarone was superior to placebo (OR 11.0, CrI 3.2\u201341.0), flecainide vs. amiodarone (OR 0.79, CrI 0.19\u20133.1), and propafenone vs. amiodarone (OR 0.36, CrI 0.092\u20131.4) were not statistically different, and flecainide was superior to propafenone (OR 2.2, CrI 1.1\u20134.8). Atrial and ventricular tachyarrhythmias, bradyarrhythmias, and hypotension were rare with PO AADs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Single oral dose Class 1C AADs are effective and safe for cardioversion of recent-onset AF. Flecainide may be superior to propafenone. Amiodarone is a slower acting alternative.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euab014","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T16:24:17Z","timestamp":1610209457000},"page":"1200-1210","source":"Crossref","is-referenced-by-count":17,"title":["Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-182X","authenticated-orcid":false,"given":"Omar A","family":"Ibrahim","sequence":"first","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie P","family":"Belley-C\u00f4t\u00e9","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J","family":"Um","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-6569","authenticated-orcid":false,"given":"Adrian","family":"Baranchuk","sequence":"additional","affiliation":[{"name":"Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2555-1266","authenticated-orcid":false,"given":"Alexander P","family":"Benz","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-8452","authenticated-orcid":false,"given":"Shreyash","family":"Dalmia","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang N","family":"Wang","sequence":"additional","affiliation":[{"name":"Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Alhazzani","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-5251","authenticated-orcid":false,"given":"David","family":"Conen","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-637X","authenticated-orcid":false,"given":"P J","family":"Devereaux","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P","family":"Whitlock","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff S","family":"Healey","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6082-7542","authenticated-orcid":false,"given":"William F","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, 20 Copeland Ave, Hamilton, ON, L8L2X2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"2021080909024485800_euab014-B1","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","article-title":"Lifetime risk for development of atrial fibrillation: the Framingham heart study","volume":"110","author":"Lloyd-Jones","year":"2004","journal-title":"Circulation"},{"key":"2021080909024485800_euab014-B2","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.114.008201","article-title":"Contemporary trends of hospitalization for atrial fibrillation in the united states, 2000 through 2010 implications for healthcare planning","volume":"129","author":"Patel","year":"2014","journal-title":"Circulation"},{"key":"2021080909024485800_euab014-B3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.cjca.2018.08.026","article-title":"2018 focused update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation","volume":"34","author":"Andrade","year":"2018","journal-title":"Can J Cardiol"},{"key":"2021080909024485800_euab014-B4","first-page":"e1\u201376","article-title":"AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of Cardiology\/American heart association task force on practice guidelines and the heart rhythm society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2021080909024485800_euab014-B5","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"2021080909024485800_euab014-B6","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1056\/NEJMoa041233","article-title":"Outpatient treatment of recent-onset atrial fibrillation with the \u201cpill-in-the-pocket\u201d approach","volume":"351","author":"Alboni","year":"2004","journal-title":"N Engl J Med"},{"key":"2021080909024485800_euab014-B7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-5273(02)00467-9","article-title":"Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation","volume":"87","author":"Khan","year":"2003","journal-title":"Int J Cardiol"},{"key":"2021080909024485800_euab014-B8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0735-1097(00)01116-5","article-title":"Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation","volume":"37","author":"Khan","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2021080909024485800_euab014-B9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0167-5273(02)00477-1","article-title":"Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation","volume":"89","author":"Khan","year":"2003","journal-title":"Int J Cardiol"},{"key":"2021080909024485800_euab014-B10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1023\/B:PHAR.0000018593.02291.c0","article-title":"Oral antiarrhythmic drugs in converting recent onset atrial fibrillation","volume":"26","author":"Deneer","year":"2004","journal-title":"Pharm World Sci"},{"key":"2021080909024485800_euab014-B11","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2021080909024485800_euab014-B12","author":"Higgins","year":"2011"},{"key":"2021080909024485800_euab014-B13","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"2021080909024485800_euab014-B14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2021080909024485800_euab014-B15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jclinepi.2018.08.022","article-title":"GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks","volume":"105","author":"Brignardello-Petersen","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2021080909024485800_euab014-B16","year":"2014"},{"key":"2021080909024485800_euab014-B17","volume-title":"R: A Language and Environment for Statistical Computing","year":"2019"},{"key":"2021080909024485800_euab014-B18","author":"Wickham","year":"2017"},{"key":"2021080909024485800_euab014-B19","author":"Dias","year":"2018"},{"key":"2021080909024485800_euab014-B20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2288-8-79","article-title":"Undue reliance on I2 in assessing heterogeneity may mislead","volume":"8","author":"R\u00fccker","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"2021080909024485800_euab014-B21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/heart.84.1.37","article-title":"Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation","volume":"84","author":"Alp","year":"2000","journal-title":"Heart"},{"key":"2021080909024485800_euab014-B22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0002-9149(96)00401-8","article-title":"Conversion of recent-onset atrial fibrillation by a single oral dose of Pilsicainide (Pilsicainide suppression trial on atrial fibrillation)","volume":"78","author":"Atarashi","year":"1996","journal-title":"Am J Cardiol"},{"key":"2021080909024485800_euab014-B23","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/oxfordjournals.eurheartj.a015146","article-title":"Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study","volume":"18","author":"Azpitarte","year":"1997","journal-title":"Eur Heart J"},{"key":"2021080909024485800_euab014-B24","first-page":"600","article-title":"Pharmacological conversion of recent atrial fibrillation: a randomized, placebo-controlled study of three antiarrhythmic drugs","volume":"11","author":"Balla","year":"2011","journal-title":"Anadolu Kardiyol Derg"},{"key":"2021080909024485800_euab014-B25","first-page":"ii16","article-title":"Adjunctive dose of oral flecainide or propafenone in acute management of atrial fibrillation patients on top 1 C antiarrhythmic drug therapy","volume":"15(Suppl_2","author":"Bolognesi","year":"2013","journal-title":"Europace"},{"key":"2021080909024485800_euab014-B26","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1111\/j.1540-8159.1998.tb01203.x","article-title":"Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols","volume":"21","author":"Boriani","year":"1998","journal-title":"Pacing Clin Electrophysiol"},{"key":"2021080909024485800_euab014-B27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1378\/chest.108.2.355","article-title":"Propafenone for conversion of recent-onset atrial fibrillation: a controlled comparison between oral loading dose and intravenous administration","volume":"108","author":"Boriani","year":"1995","journal-title":"Chest [Internet]"},{"key":"2021080909024485800_euab014-B28","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1111\/j.1540-8159.1998.tb01205.x","article-title":"Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation","volume":"21","author":"Botto","year":"1998","journal-title":"Pacing Clin Electrophysiol"},{"key":"2021080909024485800_euab014-B29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0167-5273(96)02841-0","article-title":"Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens","volume":"58","author":"Botto","year":"1997","journal-title":"Int J Cardiol"},{"key":"2021080909024485800_euab014-B30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0002-9149(94)90915-6","article-title":"Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide","volume":"74","author":"Capucci","year":"1994","journal-title":"Am J Cardiol"},{"key":"2021080909024485800_euab014-B31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9149(92)91392-H","article-title":"Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension","volume":"70","author":"Capucci","year":"1992","journal-title":"Am J Cardiol"},{"key":"2021080909024485800_euab014-B32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0167-5273(98)00363-5","article-title":"Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study","volume":"68","author":"Capucci","year":"1999","journal-title":"Int J Cardiol"},{"key":"2021080909024485800_euab014-B33","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.hrthm.2015.02.014","article-title":"COR-ART: a multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm","volume":"12","author":"Dittrich","year":"2015","journal-title":"Heart Rhythm"},{"key":"2021080909024485800_euab014-B34","first-page":"521","article-title":"Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: a randomized, prospective study","volume":"16","author":"Kosior","year":"2009","journal-title":"Cardiol J"},{"key":"2021080909024485800_euab014-B35","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1111\/j.1540-8159.2000.tb07043.x","article-title":"Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial","volume":"23","author":"Kumagai","year":"2000","journal-title":"Pacing Clin Electrophysiol"},{"key":"2021080909024485800_euab014-B36","first-page":"475","article-title":"Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: a randomized trial","volume":"1","author":"Madonia","year":"2000","journal-title":"Ital Heart J"},{"key":"2021080909024485800_euab014-B37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0002-9149(99)00789-4","article-title":"Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation","volume":"85","author":"Peuhkurinen","year":"2000","journal-title":"Am J Cardiol"},{"key":"2021080909024485800_euab014-B38","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.hrthm.2016.04.012","article-title":"Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR","volume":"13","author":"Piccini","year":"2016","journal-title":"Heart Rhythm."},{"key":"2021080909024485800_euab014-B39","first-page":"19","article-title":"Propafenone versus ibutilide for post operative atrial fibrillation following cardiac surgery: neither strategy improves outcomes compared to rate control alone (the PIPAF study)","volume":"9","author":"Soucier","year":"2003","journal-title":"Med Sci Monit"},{"key":"2021080909024485800_euab014-B40","first-page":"175","article-title":"Pharmacological conversion of recent onset atrial fibrillation: a randomized study of propafenone and amiodarone","volume":"125","author":"Taha","year":"2013","journal-title":"Cardiol J"},{"key":"2021080909024485800_euab014-B41","first-page":"408","article-title":"Comparison of a single oral dose of propafenone with a single intravenous dose of amiodarone in converting paroxysmal atrial fibrillation","volume":"40","author":"Tsaknakis","year":"1999","journal-title":"Hell J Cardiol"},{"key":"2021080909024485800_euab014-B42","first-page":"564","article-title":"Efficacia del trattamento orale on flecanide nella fibrillazione atriale parossistica: correlazione con le concentrazioni plastamiche","volume":"20","author":"Villani","year":"1990","journal-title":"G Ital Cardiol"},{"key":"2021080909024485800_euab014-B43","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/01.CIR.0000055314.10801.4F","article-title":"Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand","volume":"107","author":"Schotten","year":"2003","journal-title":"Circulation"},{"key":"2021080909024485800_euab014-B44","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1253\/circj.68.568","article-title":"Progressive nature of paroxysmal atrial fibrillation - observations from a 14-year follow-up study","volume":"68","author":"Kato","year":"2004","journal-title":"Circ J"},{"key":"2021080909024485800_euab014-B45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/europace\/eum276","article-title":"Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode","volume":"10","author":"Cosio","year":"2007","journal-title":"Europace"},{"key":"2021080909024485800_euab014-B46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jacc.2003.08.037","article-title":"Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the rate control versus electrical cardioversion (RACE) study","volume":"43","author":"Hagens","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2021080909024485800_euab014-B47","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/europace\/euq007","article-title":"Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life","volume":"12","author":"Gu\u00e9don-Moreau","year":"2010","journal-title":"Europace"},{"key":"2021080909024485800_euab014-B48","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.jacc.2005.07.040","article-title":"Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) functional status substudy","volume":"46","author":"Chung","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2021080909024485800_euab014-B49","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/01.CIR.0000121736.16643.11","article-title":"Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study","volume":"109","author":"Corley","year":"2004","journal-title":"Circulation"},{"key":"2021080909024485800_euab014-B50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7861\/clinmedicine.17-5-419","article-title":"Cardioverting acute atrial fibrillation and the risk of thromboembolism: not all patients are created equal","volume":"17","author":"Rankin","year":"2017","journal-title":"Clin Med"},{"key":"2021080909024485800_euab014-B51","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijcard.2014.01.099","article-title":"Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study","volume":"172","author":"Crijns","year":"2014","journal-title":"Int J Cardiol"},{"key":"2021080909024485800_euab014-B52","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1368-5031.2005.00705.x","article-title":"Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation","volume":"59","author":"Zhang","year":"2005","journal-title":"Int J Clin Pract"},{"key":"2021080909024485800_euab014-B53","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1378\/chest.103.4.1068","article-title":"Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function","volume":"103","author":"Santinelli","year":"1993","journal-title":"Chest"},{"key":"2021080909024485800_euab014-B54","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9149(84)90510-1","article-title":"Effects of flecainide on ventricular function: clinical and experimental correlations","volume":"53","author":"Josephson","year":"1984","journal-title":"Am J Cardiol"},{"key":"2021080909024485800_euab014-B55","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"2021080909024485800_euab014-B56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/europace\/euq382","article-title":"Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation","volume":"13","author":"Aliot","year":"2011","journal-title":"Europace"},{"key":"2021080909024485800_euab014-B57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0002-9149(96)00673-X","article-title":"Impact of the food and drug administration approval of flecainide and encainide on coronary artery disease mortality: putting deadly medicine to the test","volume":"79","author":"Anderson","year":"1997","journal-title":"Am J Cardiol"},{"key":"2021080909024485800_euab014-B58","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1900353","article-title":"Early or delayed cardioversion in recent-onset atrial fibrillation","volume":"380","author":"Pluymaekers","year":"2019","journal-title":"N Engl J Med"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/23\/8\/1200\/39606022\/euab014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/23\/8\/1200\/39606022\/euab014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T09:12:12Z","timestamp":1628500332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/23\/8\/1200\/6173081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,3,16]]},"published-print":{"date-parts":[[2021,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euab014","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,3,16]]}}}